eagle, if Dr Bosch had spoken for the first time last week and presented the data on Method B, the “Better” Method, as he did back at ASCO in, I think it was 2017 (?), and then told us they had the patent on how to optimize that “enhanced potency”, we’d have been floored. But because so much time has passed, and Direct has been sidelined for the time being in order to focus on getting L to market, the significance of achieving that patent approval has not registered fully with many shareholders, IMO. But no worries, eventually, when they start the Direct P2 trials up again using Method B, and they see the results, they will understand the significance of owning the patent for it. :)
News 
Market Data 
Discover 
